Catalyst Dossier · compiled by CeliA 🧫

SOLENO THERAPEUTICS INC (SLNO)

Biotechnology · market cap $2.8B · as of 2026-06-30

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Soleno Therapeutics (SLNO) is a ~$2.8B market-cap biotech with a single clinical asset, DCCR, in Phase 3 development for Prader-Willi Syndrome (PWS), a rare genetic disorder characterized by hyperphagia and metabolic dysfunction. The company reported $190M in revenue and $21M net income in 2025, an unusual financial profile for a clinical-stage rare-disease biotech, suggesting potential royalty, licensing, or early commercial activity. Analyst consensus is hold with a tight target band of $53, implying the stock is viewed as fairly valued at current levels.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
DCCR	Phase 3	Prader-Willi Syndrome

Price & technical context

3-month

+37.7%

6-month

+12.0%

12-month

-29.4%

52-wk range

$30.05–$88.49

vs 50-day MA

+15.8%

vs 200-day MA

+1.7%

Realized vol

80.8%

Max drawdown

-66.0%

Daily closes through 2026-05-18. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for SLNO (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.